Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas

Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that are associated with high rates of morbidity and mortality because of their large tumor burden and location, progression, and release of catecholamines. Systemic therapies for MPPGs are limited. MPPGs are cha...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancers (Basel)
Главные авторы: Jimenez, Camilo, Subbiah, Vivek, Stephen, Bettzy, Ma, Junsheng, Milton, Denai, Xu, Mingxuan, Zarifa, Abdualrazzak, Akhmedzhanov, Fechukwu Omolara, Tsimberidou, Apostolia, Habra, Mouhammed Amir, Rodon Anhert, Jordi, Fu, Siqing, Naing, Aung
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465458/
https://ncbi.nlm.nih.gov/pubmed/32824391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082307
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы